XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash Flows from Operating Activities    
Net income (loss) $ 10,228 $ (3,147)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Amortization 1,087 1,020
Depreciation 1,029 874
Income from investments in equity securities, net (200) (274)
Charge for the acquisition of Harpoon Therapeutics, Inc. 656 0
Charge for the acquisition of Prometheus Biosciences, Inc. 0 10,217
Charge for the acquisition of Imago BioSciences, Inc. 0 1,192
Deferred income taxes (232) (632)
Share-based compensation 379 314
Other 174 5
Net changes in assets and liabilities (4,394) (4,526)
Net Cash Provided by Operating Activities 8,727 5,043
Cash Flows from Investing Activities    
Capital expenditures (1,652) (1,972)
Purchases of securities and other investments (64) (587)
Proceeds from sales of securities and other investments 320 785
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired (746) 0
Acquisition of Prometheus Biosciences, Inc., net of cash acquired 0 (10,705)
Acquisition of Imago BioSciences, Inc., net of cash acquired 0 (1,327)
Other (303) 4
Net Cash Used in Investing Activities (2,445) (13,802)
Cash Flows from Financing Activities    
Net change in short-term borrowings 0 1,937
Proceeds from issuance of debt 3,600 5,946
Payments on debt (751) (1,751)
Dividends paid to stockholders (3,936) (3,738)
Purchases of treasury stock (373) (487)
Proceeds from exercise of stock options 160 112
Other (298) (315)
Net Cash (Used in) Provided by Financing Activities (1,598) 1,704
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (220) (6)
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 4,464 (7,061)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets) 6,909 12,773
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $69 and $52 at June 30, 2024 and 2023, respectively, included in Other current assets) $ 11,373 $ 5,712